The mTOR (mammalian Target of Rapamycin) inhibitor rapamycin (RAPA) is of great interest as a possible re-positioned drug for β-thalassemia and sickle-cell disease (SCD), as it is already used in patients undergoing kidney transplantation [10]. This evidence concerns the gene MTOR and sickle cell disease.